Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.10.2019 | Case report

Gemcitabine/paclitaxel

Various toxicities: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Fußnoten
1
Patient demographics were obtained via communication with the author.
 
Literatur
Zurück zum Zitat Petrillo A, et al. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Medical Oncology 36: No. 83, Oct 2018. Available from: URL: http://doi.org/10.1007/s12032-019-1306-9 - Italy Petrillo A, et al. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Medical Oncology 36: No. 83, Oct 2018. Available from: URL: http://​doi.​org/​10.​1007/​s12032-019-1306-9 - Italy
Metadaten
Titel
Gemcitabine/paclitaxel
Various toxicities: 3 case reports
Publikationsdatum
01.10.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-68928-y

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Etanercept

Case report

Propranolol

Case report

Clopidogrel

Case report

Hypersexuality